testPosted onOctober 11, 2022 11:29 am

Test111Posted onOctober 11, 2022 11:28 am

Posted onSeptember 26, 2021 1:49 pm

Thank you, Professor Mohty, for addressing this question! Antonio Macedo, BrazilPosted onSeptember 26, 2021 1:07 pm

To all speakers, how do you assess ECOG as a contraindication for CAR T-cell therapy in practice, since, at least in some cases, ECOG might actually improve after bridging therapy and CAR T-cell therapy due to control of the baseline disease? Antonio Macedo, BrazilPosted onSeptember 26, 2021 12:57 pm

What chemo bridging are you using for elderly DLBCl And what bridging Chemo for follicular lymphoma Posted onSeptember 26, 2021 12:54 pm

************* Closing session ***********Posted onSeptember 26, 2021 12:04 pm

In DLBCl anti cd19 bites in some case reports stop work b4 or after CARt any comments on challenge of CD19 check b4 or after CARt Posted onSeptember 26, 2021 11:50 am

A DLBCL relapsed after ASCT or refractory to 2 or more prior therapies could have access to CAR-T cells therapy either to alloHSCT, what is your policy? and an HLA identical sibling could be the nodal information to choose between the two strategies? Thanks (Enrico Santinelli - Italy)Posted onSeptember 26, 2021 11:11 am

*****Posted onSeptember 26, 2021 10:51 am

Could be the monitoring of CAR-T cell population on peripheral blood, if feasible, in patients with B-ALL R/R achieving CR after CAR-T cell therapy, a strategy to define the allogeneic HSCT timing. In other words could be the CAR-T cell population disappearance on peripheral blood in patients reaching CR the best moment to proceed to allo-HSCT? Thanks (Enrico Santinelli - Italy)Posted onSeptember 26, 2021 10:42 am

Would the relapse risk increase with ROCKi like in other IST?Posted onSeptember 26, 2021 9:56 am

what is about use of thalidomide and imatinib for GVHD fibrotic skin Marcos Hernandez VenezuelaPosted onSeptember 26, 2021 9:39 am

Do you see a delay in engrefament and more toxicity during the first 30 days following aloSCT with postCy? Posted onSeptember 26, 2021 8:57 am

**********************Posted onSeptember 26, 2021 8:38 am

Is there any experience with allo-HSCT in SAA Jehovah's Witness patients? 10 years ago, I had a dramatic case of a young JW with SAA unresponsive to CSP that died. HSCT could have changed the fatal outcome? (R. Camara, Spain)Posted onSeptember 26, 2021 8:36 am

Thanks for the excellent talks! Haplo donor or 9/10 unrelated with PTCY if both available? Plerixafor for allogeneic poor mobilizers or further GCSF stimulation? Posted onSeptember 26, 2021 8:21 am

What about haploidentical unrelated donors? Could these donors be an option for adult patients without haplo donors? (R.CAmara, Spain) Posted onSeptember 26, 2021 8:19 am

Great talks. Congratulations to the iach teamPosted onSeptember 26, 2021 8:10 am

Belamaf is very toxic... you think dose should be less? Artur Jurczyszyn PolandPosted onSeptember 25, 2021 5:41 pm

What will be the recommended treatment regimen for a patient with CNS involvement who is refractory to bortezomib, lenalidomide and carfilzomib? Thank you! Saliangi Wu (Hong Kong)Posted onSeptember 25, 2021 4:15 pm

Thank you! Incredible session! Antonio Macedo, BrazilPosted onSeptember 25, 2021 3:19 pm

this was jakobPosted onSeptember 25, 2021 2:54 pm

How do I join? Posted onSeptember 25, 2021 2:54 pm

Is your practice to transplant all BPCDN patients who achieve a clinical remission? Posted onSeptember 25, 2021 2:42 pm

Is haploidentical transplant indicated first line in sAA?Posted onSeptember 25, 2021 2:28 pm

How to treat peripheral neuropathy in Waldenstrom?Posted onSeptember 25, 2021 2:27 pm

Is there still room for high dose chemo in BPDCN at the era of antibodies?Posted onSeptember 25, 2021 2:01 pm

We usually see a delay in mastocytosis diagnosis? How to speed up the diagnosis?Posted onSeptember 25, 2021 2:00 pm

Posted onSeptember 25, 2021 1:43 pm

Hi there. Thanks for the presentation. In a young patient, without comorbidities, with a diagnosis of plasmacytoid dendritic cell neoplasia with isolated skin involvement (without obvious hematological involvement), what treatment would you choose? Uriel Suárez, SPAIN. Posted onSeptember 25, 2021 1:43 pm

Hi there. Thanks for the presentation. In a young patient, without comorbidities, with a diagnosis of plasmacytoid dendritic cell neoplasia with isolated skin involvement (without obvious hematological involvement), what treatment would you choose? SPAIN. Posted onSeptember 25, 2021 1:43 pm

******** Session 5 *******Posted onSeptember 25, 2021 1:39 pm